Moreover, if FAB‐M3/t(15;17) patients were excluded, non‐M3 AML cases with NEDD9 overexpression still showed markedly shorter OS and LFS time than those without NEDD9 overexpression (Figure 3). The gene discussed is NEDD9; the disease is acute myeloid leukemia.